Cancer ward for children at IGIMS to start functioning in June: Minister
1
2
3
Patna: The cancer ward for children at IGIMS here will start functioning from June, state health minister Mangal Pandey said on Friday after laying the foundation stone for the construction of a boundary wall, concrete road, drain and cable trench with an estimated expenditure of Rs16 crore on the hospital campus.
"Two state-of-the-art operation theatres, physiotherapy machines and two dozen dialysis machines, besides a 20-bed creative care medicine unit at the IGIMS will also be inaugurated next month," the minister said, adding a multi-level car parking will be constructed on its campus as well at a cost of over Rs 76 crore like Patna Medical College and Hospital.
Pandey further said work was going on projects worth Rs 701 crore at IGIMS, and further plans worth Rs 300 crore had also been approved for the expansion of health facilities there.
"The state govt has made a provision of Rs 1,050 crore to develop IGIMS as a super specialty hospital of eastern India. "The number of seats for MBBS studies in IGIMS has now increased to 150. At present, a total of 1,700 beds are available here and an equal number of beds are being added. A lecture theatre will also be constructed at a cost of over Rs 96 crore, hostel for MBBS students for over Rs18 crore and an eight-storey dental hospital building will also come up at a cost of over Rs 91 crore at the IGIMS," he said.
Digha MLA Sanjeev Chaurasia presided over the function in the presence of IGIMS director Dr Binde Kumar, hospital superintendent Dr Manish Mandal and Bihar Medical Infrastructure Development Corporation MD Dharmendra Kumar.
Get the latest lifestyle updates on Times of India, along with
Brother's Day wishes
,
messages
and quotes !
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
United News of India
3 hours ago
- United News of India
Telangana Cabinet okays pending DAs for govt staff
Hyderabad, May 6 (UNI) In the backdrop of employee unions threatening agitation over long pending demands, the Telangana Cabinet has approved the release of two pending Dearness Allowances (DAs) to the staff and also sanctioned Rs 700 crore to clear their pending bills. Briefing the media after a marathon cabinet meeting chaired by Chief Minister a Revanth Reddy held here on Thursday night, Deputy Chief Minister Bhatti Vikramarka said that a part of the two DAs will be implemented immediately, and another six months. Bhatti, who heads the cabinet sub-committee on employees' grievances, gave a detailed presentation and said it was decided that the pending bills of employees amounting to ₹700 crore per month should be cleared without delay. About the health insurance scheme for employees, he said a trust would be set up under the leadership of the chief secretary and officials would be members of the trust. Under the scheme, each employee will contribute ₹500 per month, and the government will contribute an equal amount, the Deputy CM said. He said the government accepted the employee unions' demand for a 12.5 per cent quota in the secretariat. The government was also inclined to form a medical invalidation committee to assess cases of medical retirement, he said. The cabinet decided not to re-employ retired employees, he said. Referring to grading of panchayat staff, Bhatti said employees working in village panchayats would be graded according to the panchayats' classification. The Departmental Promotion Committee (DPC) will be set up for processing employees' promotions, said the minister. Officers and employees who were transferred during the election period would be sent back to their original positions, he said. The government agreed to establish a director of nursing, he said, adding the Cabinet decided to increase Rs 2 lakh towards retirement benefits for Anganwadi workers. The pending bills related to government officials' rental vehicles would be cleared, and the vehicle limits will be revised upwards, he added. UNI KNR PRS
NDTV
4 hours ago
- NDTV
Universal Artificial Blood For All Types In Clinical Trials, Could Save Millions
In a medical breakthrough that could save millions of lives, Japanese researchers have started clinical trials to explore the effectiveness and safety of universal artificial blood. Led by Professor Hiromi Sakai at Nara Medical University, the artificial blood, usable for all blood types, could have a shelf life of up to two years. If successful, it could transform the emergency medicare system across the globe. Their approach involves extracting haemoglobin, the oxygen-carrying molecule in red blood cells, from expired donor blood. It is then encased in a protective shell to create stable, virus-free artificial red blood cells, according to a report in Newsweek. Unlike donated blood, these artificial cells have no blood type, eliminating the need for compatibility testing and making them invaluable in emergencies. Notably, donated blood has a shelf life of just 42 days, and even then, there is not enough of it, and requires compatibility amongst different blood groups. For the trial, the researchers administered 100 to 400 millilitres of the artificial blood to 16 healthy adult volunteers in March. If the test safety and efficacy are achieved, the researchers are hoping for practical use by 2030, making Japan the first country in the world to deploy artificial blood for real-world medical care. "The need for artificial blood cells is significant as there is currently no safe substitute for red cells," said Professor Sakai. Social media reacts Reacting to the start of the clinical trials, social media users marvelled at the potential implications with some claiming it was a Nobel Prize-winning endeavour, if it was a success. "If true, and not inordinately expensive, this is going to be completely transformational," said one user, while another added: "If it is safe, this is worth a Nobel Prize." A third commented: "Japanese scientists are really doing the most between this, regrowing teeth, and the shots that make cats live longer. Really hope this stuff makes it worldwide." Notably, the US has been developing ErythroMer (made from 'recycled' haemoglobin) for the past few years, and has already started pre-clinical testing. Last year, the Defense Advanced Research Projects Agency (DARPA) announced a Rs 394 crore ($46 million) grant to a University of Maryland-led consortium to develop a shelf-stable, field-deployable whole blood substitute with ErythroMer as its core.
Economic Times
4 hours ago
- Economic Times
Dr. Reddy's shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Dr. Reddy's Laboratories rose 1.4% to touch the day's high of Rs 1,307.65 on the BSE on Friday, June 6, after the company announced a strategic collaboration with Alvotech , a global biotech firm, to co-develop and commercialize a biosimilar candidate to Keytruda ( pembrolizumab ) for global markets.'Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines, and Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's'), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets,' Dr. Reddy's said in an exchange a leading immunotherapy drug used in the treatment of various cancers, generated $29.5 billion in global sales in 2024, making it one of the most valuable targets in the biosimilars partnership represents a significant opportunity for Dr. Reddy's to enter the high-value biosimilar segment for oncology drugs, a category that continues to witness growing demand and heightened competitive the agreement, both parties will jointly develop and manufacture the biosimilar, sharing costs and responsibilities. Importantly, each company will retain the right to commercialize the product globally, subject to certain deal is expected to accelerate development timelines and expand the global market reach of the biosimilar.Róbert Wessman, Chairman and CEO of Alvotech, emphasized that the agreement will help deliver cost-effective, critical biologic medicines to patients worldwide by combining Dr. Reddy's commercial strength with Alvotech's R&D and manufacturing this collaboration, Dr. Reddy's further strengthens its pipeline in the biosimilars segment.'We are pleased to collaborate with Alvotech on the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high-quality, affordable treatment options for patients across the world. Oncology has been a key focus area for us, and this collaboration will enhance our capabilities in this domain, as pembrolizumab represents one of the most critical therapies in immuno-oncology,' said Erez Israeli, CEO of Dr. Reddy' Reddy's Laboratories shares ended Thursday's session higher by 3% at Rs 1,289.90 on BSE.
